0
     

Biosimilars Market Trends Influence the Healthcare Industry

Jan 14,2022 | Biotechnology

Biosimilars can be defined as large and complex molecules that are produced from living organisms such as animal cells and microorganisms. To ensure consistent quality, biosimilar drugs are carefully observed. Moreover, the medication has been approved by the Food and Drug Administration in the US to treat diseases and conditions such as cancer, diabetes, rheumatoid arthritis, psoriasis and colitis among others. 

The Global Biosimilars market will reach US$113.25 billion by 2030, growing by 25.7% annually over 2020-2030 driven by the affordability of biosimilar-based treatment, rising incidence of chronic diseases due to aging populations, patent expirations of many blockbuster drugs and better healthcare provisions.

Offered by Bharatbook under the life science industry and healthcare service market research reports, the Global Biosimilars Market analysis 2020-2030 is based on a comprehensive research of the entire global biosimilars market and all its sub-segments through extensively detailed classifications.

Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from the healthcare industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global biosimilars market in every aspect of the classification from perspectives of Product Type, Indication, Manufacturing, End User, and Region. Based on Product Type, the global market includes Recombinant Non-glycosylated Biosimilars, Recombinant Human Growth Hormone (rHGH), Recombinant Glycosylated Biosimilars and Recombinant Peptides and Others.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players include
AMEGA Biotech S.A., Apotex Inc., Biocon Ltd, Biogen Inc., Boehringer Ingelheim, Celltrion, Inc., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Intas Pharmaceuticals Ltd., LG Chem, Ltd., Merck and Co. Inc., Mylan N.V., Pfizer Inc., Samsung Biologics Co., Ltd., Sandoz International GmbH, STADA Arzneimittel AG and Teva Pharmaceutical Industries Ltd.

For more details about the market, we recommend you to visit - Global Biosimilars Market.